Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Novartis AG. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG (“Novartis” or “the Company”) (NYSE: NVS). Investors who purchased Novartis securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Novartis has violated federal securities laws.
Novartis Investigation Details
On September 8, 2026, Novartis issued a press release “announc[ing] that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia.” On this news, Novartis’s American Depositary Share (“ADS”) price fell $22.29 per ADS, or 13.93%, to close at $137.70 per ADS on September 8, 2026.
What’s Next for Novartis Investors?
If you are aware of any facts relating to this investigation or purchased Novartis securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
NVS — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”